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Abstract
CDK5R1 encodes p35, a specific activator of the serine/threonine kinase CDK5, which plays crucial roles in CNS development
and maintenance. CDK5 activity strongly depends on p35 levels and p35/CDK5 misregulation is deleterious for correct CNS
function, suggesting that a tightly controlled regulation of CDK5R1 expression is needed for proper CDK5 activity.
Accordingly, CDK5R1 expression was demonstrated to be controlled at both transcriptional and post-transcriptional levels,
but a possible regulation through microRNAs (miRNAs) has never been investigated. We predicted, within the large CDK5R1
39UTR several miRNA target sites. Among them, we selected for functional studies miR-103 and miR-107, whose expression
has shown a strong inverse correlation with p35 levels in different cell lines. A significant reduction of CDK5R1 mRNA and
p35 levels was observed after transfection of SK-N-BE neuroblastoma cells with the miR-103 or miR-107 precursor (pre-miR-
103 or pre-miR-107). Conversely, p35 levels significantly increased following transfection of the corresponding antagonists
(anti-miR-103 or anti-miR-107). Moreover, the level of CDK5R1 transcript shifts from the polysomal to the subpolysomal
mRNA fraction after transfection with pre-miR-107 and, conversely, from the subpolysomal to the polysolmal mRNA fraction
after transfection with anti-miR-107, suggesting a direct action on translation efficiency. We demonstrate, by means of
luciferase assays, that miR-103 and miR-107 are able to directly interact with the CDK5R1 39-UTR, in correspondence of a
specific target site. Finally, miR-103 and miR-107 overexpression, as well as CDK5R1 silencing, caused a reduction in SK-N-BE
migration ability, indicating that these miRNAs affect neuronal migration by modulating CDK5R1 expression. These findings
indicate that miR-103 and miR-107 regulate CDK5R1 expression, allowing us to hypothesize that a miRNA-mediated
mechanism may influence CDK5 activity and the associated molecular pathways.
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Introduction
Human CDK5R1 (Cyclin-dependent kinase 5, regulatory subunit 1,
GeneID: 8851) encodes p35, a specific activator of Cyclin-
dependent kinase 5 (CDK5, GeneID: 1774), which is a proline-
directed serine/threonine kinase. Monomeric CDK5 shows no
enzymatic activity and requires association with p35 or p39 for
activation [1]. While Cdk5 is expressed ubiquitously in mamma-
lian tissues, its activator proteins are predominantly expressed in
postmitotic neurons: for this reason its activity has mainly been
associated with the central nervous system (CNS) development and
function [2,3].
The functions of Cdk5 that have been best characterized mainly
involve CNS development and maintenance, and are mediated by
the phosphorylation of its several substrates [2,3].
The association of p35 with Cdk5 is required for neuronal
survival and is involved in many fundamental processes during
neuronal differentiation and function such as neurite outgrowth [4],
axon regeneration [5], neuronal apoptosis [6], synaptic plasticity,
learning and memory [7] and membrane trafficking during the
outgrowth of neuronal processes [8], with a role also in secretion
and dopamine signalling by controlling cytoskeletal dynamics [9].
Furthermore, Cdk5 and p35 are essential for radial migration
and lamination of cortical neurons during the morphogenesis of
the mammalian cerebral cortex. Cdk5 knockout mice display
severe cortical lamination defects and perinatal death [10].
Similarly, Cdk5r1 KO mice show severe cortical lamination defects
and suffer from adult mortality and seizures [11]. Cdk5
hyperactivation, associated to p35 overexpression and production
of p25, a proteolytic fragment containing the C-terminal portion
of p35 [12], has been implicated in some neurodegenerative
disorders, such as Alzheimer’s disease (OMIM: 104300) [13],
Parkinson’s disease (OMIM: 168600) [14] and amyotrophic lateral
sclerosis (OMIM: 105400) [15]. More recently, CDK5R1 has been
indicated as a candidate for mental retardation in the NF1-
microdeletion syndrome (OMIM: 162200) [16].
The deleterious effects of CDK5 and CDK5R1 dysregulation
during both physiological and pathological processes strongly
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20038
suggest that a precise spatio-temporal regulation of CDK5R1
expression is needed for a proper activation of CDK5. It has
been shown that p35 cellular level is the main limiting factor
for the CDK5 kinase activity [17], but little is known about the
regulation of p35 expression. Some data on the regulation of
CDK5R1 transcription have been reported. TNF-a, through
activation of the ERK1/2 pathway, regulates Cdk5r1 promoter
activity in PC12 cells inducing a sustained and robust
expression of Cdk5r1, thereby increasing Cdk5 kinase activity
[18]. Moreover, IL-6 was found to affect p35 protein levels in
hippocampal neurons, and IFN-c increased p35 protein levels
in neuroblastoma Paju cells [19,20]. Some evidence of a
regulation of p35 at post-translational level has also been
reported: p35 was shown to undergo fast turnover through
ubiquitylation and proteasomal degradation [21] and it has
been recently reported that PKCd phosphorylates p35,
preventing its degradation in cultured cortical neurons and
regulating the radial migration of layer II/III cortical neurons
by stabilizing p35 [22].
We recently demonstrated that the expression of CDK5R1 can
be further modulated at post-transcriptional level by its 39-UTR
[23]. 39-UTRs play key roles in post-transcriptional regulatory
mechanisms, allowing a finely tuned spatio-temporal control of
expression of several neuronal genes coding for growth-associated
proteins [24], cytoskeletal elements [25], neurotransmitter biosyn-
thetic enzymes and receptors [26], and also proteins associated to
neurodegenerative disease such as the amyloid precursor protein
[27]. Indeed, disturbances in post-transcriptional regulation can
lead to neuronal dysfunction or, in extreme cases, to neuronal
degeneration [28].
The CDK5R1 gene displays a very large and highly
evolutionary conserved 39-UTR (2725 bp), where specific
post-transcriptional regulatory elements/effectors, such as AU-
rich regions and neuronal RNA-binding proteins ELAV
(nELAV), were shown to affect transcript stability [23].
Nevertheless, other trans-acting factors are expected to have a
role in the 39-UTR-mediated modulation of CDK5R1 expres-
sion, including an important class of post-transcriptional
regulators, the microRNAs (miRNAs). miRNAs are short, on
average only 22 nucleotides long, non-coding RNAs whose
action usually results in mRNA degradation or translation
repression, depending on the degree of sequence complemen-
tarity with the 39-UTR of their target transcripts. Animal
miRNAs typically have imperfect complementarity with their
target mRNAs [29], and this causes translational repression.
Target prediction algorithms have estimated that thousands of
human gene products are regulated by miRNAs [30]. Current
functional studies have shown that miRNAs are key regulators
of developmental processes, such as self-renewal of stem cells,
myogenesis, embryogenesis, and cellular differentiation [31–33].
Many miRNAs are expressed in the CNS, often in a temporally
and/or spatially regulated manner during development, differ-
entiation and neuronal survival, and are also potentially
involved in neuronal plasticity and learning with a reported
role in neurodegeneration [34,35].
Given the functional necessity of maintaining a correct cellular
level of p35, miRNAs are also expected to be involved in the fine
tuning of p35 expression. In the present study we report on the
identification of two miRNAs, miR-103 and miR-107, regulating
CDK5R1/p35 expression and reducing migration of the neuro-
blastoma cells SK-N-BE. Among the several predicted miRNA
binding sites, we validated the activity of one miR-107 and one
miR-103 binding site by means of functional studies based on
luciferase assays.
Results
Prediction of miRNA target sites in CDK5R1 39-UTR
In order to identify miRNAs potentially regulating CDK5R1
expression, we first searched for miRNAs predicted to target the
CDK5R1 39-UTR, using the algorithm PicTar. We found that the
39-UTR of human CDK5R1 harbours putative target sites for 20
different miRNAs (Table 1). The number of predicted binding
sites for each miRNA varies from one to 13. Moreover, each target
site can be bound by a number ranging from 1 to 8 different
miRNAs. Because the regulatory effects of miRNAs are typically
seen to increase when more than one molecule of the same
miRNA binds its targets [36], we decided to select for subsequent
study the six miRNAs (miR-195, miR-16, miR-15a, miR-15b,
miR-107 and miR-103) which were predicted to bind to the
highest number of target sites ($10).
Inverse correlation between miR-103 and miR-107
expression and p35 level in human cell lines
Preliminary RT-PCR experiments on miRNA precursors (pre-
miRs) in five neuronal and non neuronal human cell lines (SK-N-
BE, SH-SY5Y, HEK-293, DU-145, MCF-7) showed the expres-
sion of all but one (miR-15b) of the miRNAs in all of the tested cell
lines (data not shown). We then sought to identify which among
the five expressed miRNAs could be the most plausible candidates
for having a regulatory effect on CDK5R1 expression by evaluating
the expression levels of the mature miRNAs by qRT-PCR in the
above mentioned human cell lines (Figure 1A), and comparing
them with the levels of p35, encoded by CDK5R1, as quantified by
Western blot (Figure 1B). miR-34a was included in this analysis as
a negative control, given that it was not predicted to target
CDK5R1 mRNA. Neuronal cell lines (SK-N-BE and SH-SY5Y)
showed significantly lower amounts of p35 compared to the non
neuronal cell lines (HEK-293, DU-145 and MCF-7) (Figure 1B).
Each miRNA displays a particular expression profile in the studied
cell lines (Figure 1A). Since post-transcriptional miRNA-mediated
regulation usually results in gene silencing, we expect an inverse
correlation between miRNA and p35 levels in the five cell lines
only for those miRNAs which have a regulatory action on
CDK5R1 expression. We then performed a correlation analysis,
based on Pearson’s correlation coefficient, which revealed that
there is a negative correlation for all the five miRNAs, with
correlation coefficients ranging from 20.40 to 20.80 (Figure 1C).
Conversely, miR-34a did not show a negative correlation
coefficient (r = 0.66), as expected for a miRNA without predicted
targets sites in CDK5R1 39-UTR. Out of the three miRNAs with
the most negative correlation coefficients (miR-103: r =20.80;
miR-107: r =20.75; miR-16: r =20.71), we decided to focus our
attention on miR-103 and miR-107 as potential modulators of
CDK5R1 expression by virtue of the lowest free energy values of
their predicted binding sites (Table 1). Of note, miR-103 and miR-
107 have the same sequence with the exception of just one
nucleotide located outside the so-called ‘seed sequence’ and, by
consequence, share all but one of the predicted target sites.
miR-103 and miR-107 modulate CDK5R1 expression in
SK-N-BE cells
To assess the effects of miR-103 and miR-107 on endogenous
CDK5R1 expression, we transiently transfected SK-N-BE cells
with either their precursors (pre-miR-103 and pre-miR-107) or
their inhibitors (anti-miR-103 and anti-miR-107). qRT-PCR on
mature miRNAs confirmed that the transfection of the respective
miRNA precursors lead to miR-103 and miR-107 overexpres-
sion, compared to the untransfected controls. Vice versa, the
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transfection of miRNA inhibitors almost abolished the expression
of miR-103 and miR-107 (data not shown).
48 h after pre-miR-107 transfection, a significant reduction of
p35 levels was observed, by 42% with 50 nM and 51% with
100 nM of precursor, compared to the untransfected control after
normalization on GAPDH levels. Similarly, the transfection of
pre-miR-103 caused a 35% (50 nM) and a 40% (100 nM)
reduction of p35 levels (Figure 2A). Otherwise, if anti-miR-107
(50–100 nM) was transfected, an increase of 57% and 50% in p35
levels was observed, respectively, compared to the untransfected
control. Moreover, an increase of 76% (50 nM) and 83%
(100 nM) of p35 levels was observed following anti-miR-103
transfection (Figure 2B).
Total mRNA was extracted from SK-N-BE cells 48 hours after
transfection with 100 nM pre-miR-103, pre-miR-107, anti-miR-
103 and anti-miR-107. A qRT-PCR showed a decrease in
CDK5R1 transcript level after transfection with the miRNA
precursors and an increase of CDK5R1 mRNA after treatment
with the anti-miRNAs (Figure 2C). Taken together, these results
suggest that miR-103 and miR-107 can affect CDK5R1 expression
in SK-N-BE cells.
miR-107 directly regulates CDK5R1 translation
To verify whether miR-107 directly regulates the level of p35 by
affecting translation efficiency of CDK5R1 mRNA, the SK-N-BE
cell line was transfected with pre-miR-107 or anti-miR-107, then
after 48 h the mRNA–ribosomal complexes were separated
through sucrose gradient centrifugation in the polysomal and
subpolysomal fractions, containing the efficiently translated
transcripts and the untranslated mRNAs respectively. After
RNA extraction a qRT-PCR has been performed to quantify
CDK5R1 mRNA, allowing us to determine, on the basis of the DCt
values, the amount of this transcript in both polysomal and
subpolysomal compartments. The relative distributions of
CDK5R1 mRNA in the two compartments are indicated as
percentages calculated on the sum of the transcript extracted from
the two fractions, for each treatment and control (Figure 3). The
results, despite not reaching the statistical significance, show a
trend towards a shift of CDK5R1 mRNA from the polysomal to the
subpolysomal compartment after transfection with pre-miR-107
compared to the control (Figure 3), indicating that miR-107
directly acts as a negative translational regulator. On the other
hand, transfection with anti-miR-107 suggest a shift of the mRNA
from the subpolysomal to the polysomal fraction compared to the
control (Figure 3), indicating an increase in translation. These
results confirm that miR-107 directly regulates CDK5R1
expression at translational level.
miR-103 and miR-107 interact with the CDK5R1 39-UTR
To verify that miR-103 and miR-107 act on p35 levels by
directly interacting with the CDK5R1 39-UTR, we co-transfected
into SK-N-BE cells the pGL4.71P-UTR construct, containing the
whole human CDK5R1 39-UTR downstream of the Renilla
luciferase coding sequence [23], with 100 nM of pre-miR-103 or
pre-miR-107. The co-transfection in SK-N-BE of this construct
with pre-miR-103 or pre-miR-107 led to a reduction of luciferase
activity (Figure 4), in comparison to the luciferase activity
measured in the same cells transfected only with pGL4.71P-
UTR, suggesting a direct action of the two miRNAs on CDK5R1
transcript by means of interaction with its 39-UTR.
We then attempted to establish which among the different miR-
103 and miR-107 predicted target sites were the most effective in
Table 1. PicTar miRNA target sites prediction in CDK5R1 39-UTR.
microRNA # of sites Free energies (kcal/mol)
has-miR-15b 13 (2) (5) 219.2 222.5 217.6 218.6 216.8 218.2 219.7 218.1 216.3 217.1 222.5 216.1 216.0
hsa-miR-195 12 (2) (4) 216.9 217.5 218.6 218.7 217.3 218.6 220.6 217.6 221.1 216.4 217.4 219.0
has-miR-107 11 (7) (3) 225.3 221.2 222.2 219.9 219.4 219.4 224.9 224.3 223.5 224.5 216.8
has-miR-15a 11 (6) (3) 220.9 221.0 220.3 216.8 219.4 223.1 220.1 218.6 219.0 224.7 217.9
has-miR-103 10 (7) (2) 225.3 221.2 222.2 219.4 218.2 223.5 223.9 224.5 224.2 216.8
has-miR-16 10 (2) (5) 219.3 219.1 218.4 215.1 219.5 223.2 218.9 222.8 217.3 216.3
has-miR-130b 6 (4) (0) 216.1 221.5 224.8 215.9 221.9 224.6
has-miR-130a 6 (2) (1) 216.1 222.1 216.4 215.4 219.1 222.4
has-miR-33 6 (1) (1) 216.9 218.3 220.0 211.3 217.3 217.3
has-miR-183 4 (4) (0) 220.3 223.2 220.1 220.5
has-miR-27b 4 (3) (1) 220.7 222.6 218.2 222.8
has-miR-23a 4 (2) (1) 224.4 218.7 224.5 213.8
has-miR-23b 4 (2) (1) 222.4 218.2 223.1 213.8
has-miR-25 4 (1) (0) 217.2 222.5 215.4 217.9
has-miR-301 3 (2) (0) 221.1 215.8 222.0
has-miR-27a 3 (2) (0) 220.7 217.6 220.0
has-miR-152 3 (2) (0) 225.0 215.6 220.7
has-miR-148a 2 (2) (0) 220.0 221.4
has-miR-148b 2 (2) (0) 220.7 223.6
has-miR-101 1 (0) (1) 219.4
In the second column, the numbers are: number of binding sites for the given miRNA in CDK5R1 39-UTR, number of binding sites with a free energy smaller that
220.0 kcal/mol., number of binding sites with free energy between 220.0 and 218.0 kcal/mol.
doi:10.1371/journal.pone.0020038.t001
miR103/107 Regulate CDK5R1 Reducing Cell Migration
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20038
modulating CDK5R1 expression. The bioinformatic analysis of
the 39-UTR predicted the presence of 10 and 11 target sites
(S1–S11) for miR-103 and miR-107, respectively. Indeed, the
S5 site is recognised by PicTar as a target site for miR-107 but
not for miR-103. Moreover, since S2 and S3 sites, as well as S5
and S6 sites, are mostly overlapped, we treated them as single
sites, referred as to site S2/3 and S5/6, respectively. We
divided the 39-UTR into 7 regions (named R1 to R7), each of
Figure 1. Correlation between p35 and miRNAs expression in cell lines. A) Expression of mature miR-195, miR-16, miR-15a, miR-107, miR-
103 and miR-34a measured by Real-Time PCR on total RNA extracted from SK-N-BE, SH-SY5Y, HEK-293, DU-145 and MCF-7 cell lines. The expression
levels are normalised on the expression of the endogenous control RNU6B. RNU6B levels were comparable in all samples tested. B) Western blot for
p35 detection in protein extracts from the same cell lines. Expression is normalised on b-actin. A representative experiment is shown at the top of the
panel. C) Correlation analysis between each miRNA and p35 protein levels in the five cell lines, r = Pearson’s correlation coefficient.
doi:10.1371/journal.pone.0020038.g001
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them containing one or two binding sites (Figure 5A). Following
the cloning of each fragment in the pGL4.71P plasmid and the
generation of the respective constructs in which the seed region
of each site was deleted, we transfected the wild-type and the
deleted constructs in SK-N-BE cells, to investigate the activity
of endogenous miR-103 and miR-107 on each predicted
binding site (Figure 5B). Luciferase assays showed that the
reporter gene activity of all the wild-type constructs was
reduced with respect to the control pGL4.71P plasmid, which
has been set to 100. Comparison between each wild-type
fragment and the respective construct deleted of the seed region
showed a significant increase of luciferase activity following
deletion of S1 and S8, but not the remaining binding sites,
suggesting their contribution to the down-modulation of the
Figure 2. p35 protein and CDK5R1mRNA expression in pre-miR-103/107 and anti-miR-103/107 transfected and untransfected SK-N-
BE cells. A) Western blot analysis of p35 in the conditioned media of control SK-N-BE cells (lane 1 and 2), 50 nM and 100 nM pre-miR-103 and pre-
miR-107 transfected cells, at 48 h from transfection. A representative experiment is shown at the top of the panel. (*p,0.05, **p,0.01). B) Western
blot analysis of p35 in the conditioned media of control SK-N-BE cells (lane 1 and 2), 50 nM and 100 nM anti-miR-103 and anti-miR-107 transfected
cells, at 48 h from transfection. A representative experiment is shown at the top of the panel. (*p,0.05). C) CDK5R1mRNA expression level measured
by qRT-PCR after 48 h from transfection with 100 nM pre-miR-107, pre-miR-103, anti-miR-107 and anti-miR-103 normalised on housekeeping GAPDH
transcript. The level of GAPDH expression was comparable in all samples tested. (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0020038.g002
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reporter gene (Figure 5B). S1 and S8 were also deleted from the
pGL4.71P-UTR in order to study their effect on the whole 39-
UTR (Figure 5C). Only the deletion of S1 led to a significant
increase in luciferase activity.
In order to study whether miR-103 and miR-107 display
activity on S1 and S8 sites, the constructs R1, containing S1, and
R4, containing S8, have been transiently transfected and treated
with pre-miR-103 and pre-miR-107 in SK-N-BE cells. Pre-miR-
34a was used as a negative control as it does not target CDK5R1
39-UTR. As shown in Figure 5D, luciferase activity of the R1
construct is significantly diminished when transfected with miR-
103 or miR-107, while R4 construct, is not affected following
transfection with the two miRNAs, indicating that this site is not
sensitive to miR-103 and miR-107 exposition. Also, the transfec-
tion of miR-34a does not lead to any change in luciferase activity,
as expected. These data suggest that miR-103 and miR-107
display an effect on CDK5R1 regulation through the binding to the
S1 site. It is worth to be noted that the S1 site shows the lowest
hybridization free energy with miR-103 and miR-107, based on
both PicTar (Table 1) and RNAhybrid analysis (Figure S1 and S2).
miR-103, miR-107 and CDK5R1 silencing reduce the
migration ability of SK-N-BE cells
Given the fundamental role of p35 in neuronal migration and
the evidence that miR-103 and miR-107 can modulate endoge-
nous p35 levels, we examined whether their transfection also
affected SK-N-BE cell migration capacity. As shown in Figure 6,
8 hours after transfection the migration abilities of the 50 nM pre-
miR-103 and pre-miR-107 transfected cells were significantly
reduced up to 31% and 28% respectively; 24 hours after
transfection the migration abilities of the 50 nM pre-miR-103
and pre-miR-107 transfected cells were significantly reduced up to
42% and 46%. No significant effects on cell migration capacity
was seen after transfection of 50 nM control miRNA. The
inhibition percentages are calculated setting the SK-N-BE
migration ability at 100%. To support the assertion that miR-
103 and miR-107 affected the SK-N-BE migration through the
regulation of the p35 level, we knocked-down p35 by CDK5R1
siRNA transfection in SK-N-BE cells. The p35 protein levels were
decreased up to 41% at 48 hours (Figure S3, panel A) and 42% at
72 hours (Figure S3 panel B) after 50 nM and 100 nM CDK5R1
siRNA cell transfection. The p35-knocked-down cells were
subsequently monitored for their migration ability by means of a
scratch assay. 8 hours after transfection the migration abilities of
50 nM CDK5R1 siRNA transfected cells were significantly reduced
up to 23% and up to 44% at 24 hours from transfection. The
transfection of 50 nM control siRNA did not affect cellular
migration. The scratch assay was also performed transfecting
100 nM of each molecule, leading to comparable results (data not
shown). These results suggest that miR-103 and miR-107 are
involved in cell migration by p35 inhibition.
Discussion
p35, encoded by CDK5R1, is a short-lived protein and the fine
regulation of its level in the cell is crucial for CDK5 activity [21].
The regulation of p35 stability by PKCd has been recently
reported [22] and the regulatory action of CDK5R1 39-UTR on
the post-transcriptional control of its expression has also been
investigated [23], even if the influence on CDK5R1/p35 levels by
miRNAs, an important class of post-transcriptional regulatory
factors, has never been investigated.
miRNAs have been implicated in several cellular processes such
as proliferation, differentiation and apoptosis and, taking into
account the high complexity of the mammalian brain, miRNAs
emerge as important factors in the regulation of specific functions
in CNS such as neuronal migration, differentiation and synaptic
plasticity [37].
Here we have shown that miR-103 and miR-107 affect p35
expression in SK-N-BE neuroblastoma cells and their overexpres-
sion reduces cellular migration. Functional studies demonstrate the
direct action of the two miRNAs on the CDK5R1 39-UTR,
allowing us to identify a functional binding site.
Analysis of the CDK5R1 39-UTR by PicTar allowed to select six
miRNAs for the presence of more than 10 binding sites within
CDK5R1 39-UTR, interestingly belonging to the same family,
Figure 3. Effect of miR-107 on CDK5R1 mRNA in polysomal and
subpolysomal lysates. qRT-PCR of CDK5R1 mRNA in polysomal and
subpolysomal fractions. SK-N-BE cells were transfected with 100 nM
pre-miR-107 or anti-miR-107 for 48 h, then the mRNA–ribosomal
complexes were separated through sucrose gradient centrifugation.
Expression is normalized on the housekeeping Alu transcript. The
percentages of the transcript obtained from the two fractions are
calculated on the sum of the 22DCt of the mRNA from polysomal and
subpolysomal compartments, for pre-miR-107, anti-miR-107 treatments
and the control (lipofectamine).
doi:10.1371/journal.pone.0020038.g003
Figure 4. Interaction between miR-103/107 and CDK5R1 39-UTR.
The 2688 bp sequence of the CDK5R1 39-UTR was cloned upstream the
Renilla luciferase gene generating the pGL4.71P-UTR construct. This was
cotransfected into SK-N-BE cells with a firefly luciferase report vector for
luciferase normalization. Cells were treated with the transfection agent
alone (Lipofectamine) or with 100 nM pre-miR-103 or pre-miR-107.
Luciferase activity was assessed 48 h after transfection of pre-miRNAs
(*p,0.01).
doi:10.1371/journal.pone.0020038.g004
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known as the miR-15/107 family [38]. These miRNAs present an
AGCAGC motif near the critical 59 end of the mature miRNA
and are known to regulate the expression of genes involved in cell
division, metabolism, stress response and angiogenesis. The miR-
15/107 group has also been implicated in human cancers,
cardiovascular disease and neurodegenerative disease [38].
Among the selected miRNAs, miR-103 and miR-107 are those
whose expression levels showed the most negative Pearson’s
correlation coefficient when compared with p35 level. Besides they
are also predicted to bind seven target sites with a free energy
,220 kcal/mol (Figure 1, Table 1). miR-103 and miR-107 differ
in their mature sequence for only one base, thus are referred to as
paralogous miRNAs and are predicted to bind the same target
sites, except for one, in the CDK5R1 39-UTR. miR-103 is encoded
by two different genes, MIR103-1 (GeneID: 406895) and MIR103-
2 (GeneID: 406896), residing within the PANK3 (GeneID: 79646;
chromosome 5q34) and PANK2 (GeneID: 80025; chromosome
20p13) genes, respectively, which give rise to an identical mature
miRNA. Instead, the primary transcript of miR-107 (MIR107
GeneID: 406901) is co-expressed with an intronic segment of
Figure 5. Functional analysis of miR-103/107 target sites on CDK5R1 39-UTR. A) Schematic location of miRNA target sites (S1 to S11) in the
CDK5R1 39-UTR and schematic representation of the regions of 39-UTR (named from R1 to R7) used to generate the luciferase constructs. B) SK-N-BE
cells were transfected with the CDK5R1 39-UTR-luciferase constructs, each one containing one or two predicted binding sites or with the same
constructs deleted of the binding sites (named DS constructs). 24 h after transfection, cells were collected and then Renilla luciferase activities were
estimated and normalized to firefly luciferase activities. The deletion of both S1 and S8 lead to an increase in luciferase activity compared to the wild-
type construct. (*p,0.05, **p,0.01). C) SK-N-BE cells were transfected with the pGL4.71P control plasmid (no UTR), with pGL4.71P-UTR either wild-
type (UTR) or deleted of S1 (UTRDS1) or S8 (UTRDS8). Deletion of S1 leads to an increase of luciferase activity compared to the wild-type UTR.
(**p,0.01). D) Luciferase constructs R1, containing S1, and R4, containing S8, have been transiently co-transfected in SK-N-BE cells and separately
treated with 100 nM pre-miR-103 and pre-miR-107. Pre-miR-34a was used as a control as it can not bind CDK5R1 39-UTR. Luciferase activity of the R1
construct is significantly diminished when transfected with pre-miR-103 or pre-miR-107. (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0020038.g005
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Figure 6. Measurement of cell migration by in vitro scratch assay. SK-N-BE cells were transiently transfected with 50 nM pre-miR-103, pre-miR-
107 or control miR (C- miR) and with 50 nM CDK5R1 siRNA or control siRNA (C- siRNA). Themigration ability was assessed 8 h and 24 h from the scratch.
A) The figure shows the cells immediately after the scratch (T0), 8 h (T8) and 24 h (T24) after the scratch. Magnification is 106. B) After 8 h (T8) from the
scratch, themigration was inhibited by 25% in 50 nM pre-miR-107 transfected cells, by 26% in 50 nM pre-miR-103 transfected cells and by 23% in 50 nM
CDK5R1 siRNA transfected cells, compared to untransfected cells. After 24 h (T24) from the scratch, themigrationwas inhibited by 41% in 50 nM pre-miR-
107 SK-N-BE transfected cells, by 40% in 50 nM pre-miR-103 transfected cells and by 42% in 50 nM CDK5R1 siRNA transfected cells. (*p,0.01).
doi:10.1371/journal.pone.0020038.g006
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PANK1 (GeneID: 53354), a coding gene localized on chromosome
10. miR-103 and miR-107 genes are completely conserved in all
known vertebrates. They have been shown to be expressed in
many human organs with the highest concentration in brain tissue,
in particular they are abundantly expressed in upper cortical layers
and in white matter, with a laminar specificity in human prefrontal
cortex [39,40]. The two miRNAs are differentially expressed in a
number of contexts, including development [41,42], oncogenesis
[43], neurodegeneration [38], hypoxia [44], and both cold and
heat stress [45,46]. Only a few targets of miR-103 and miR-107
have currently been validated: beta-site amyloid precursor protein-
cleaving enzyme 1 (BACE1, GeneID: 933) [47], cyclin-dependent kinase 6
(CDK6, GeneID: 1777) [48], granulin (GRN, GeneID: 4601) [49]
and DICER1 (DRCE1, GeneID: 17098) [50], while the brain-derived
neurotrophic factor (BDNF, GeneID: 1033) is indicated as a potential
target [51].
The effect of miR-103 and miR-107 on p35 expression is
consistent with their direct action on both CDK5R1 mRNA
degradation, as observed by qRT-PCR on total RNA, and on
CDK5R1 mRNA translation efficiency, as established following
qRT-PCR on polysomal and subpolysomal fractions. As BDNF is
known to stabilize p35 and its transcript is also a possible target of
miR-103 and miR-107 [22,51], we cannot exclude that the effect
on p35 expression may be enhanced by BDNF action, since p35
and BDNF are both regulated by the two studied miRNAs. p35
downregulation by overexpression of miR-103 and/or miR-107 as
well as by CDK5R1 silencing lead to reduced migration ability of
SK-N-BE cells. These findings suggest that the effect of miR-103
and/or miR-107 on cellular migration acts through p35
downregulation. This proposed mechanism is in accordance with
neuronal migration impairment in Cdk5r1 KO mice, inferred by
the observation of an inverted cortex lamination [11]. This
evidence indicates that the two miRNAs can play a role in the
regulation of cellular migration, a function so far proved only for a
few miRNAs [52].
In accord, miR-103 and miR-107 can be included in the group
of seven miRNAs (miR-30a-5p, miR-30b,c,d, miR-103/107, miR-
191, miR-195) possibly involved in neuronal migration, through
the regulation of BDNF expression in human cortex [51].
Interestingly, BDNF activates PKCd which in turn stabilizes
p35, increasing CDK5 activation. PKCd was demonstrated to
regulate the radial migration of layer II/III cortical neurons and
both PKCd and p35 are required for BDNF-stimulated migration
in the culture of cortical newborn neurons [22]. Furthermore, the
correct neuronal migration and cortical lamination strongly
depends on CDK5 activation by p35, through the regulation of
motor proteins and cytoskeleton components engaged in the cell
motility [53]. It is known that p35 protein undergoes fast turn-
over in an ubiquitin- and proteasome-dependent manner [21]
and its level is rate-limiting for CDK5 activity [17]. Thus, the
maintenance of proper CDK5 activity in migrating neurons
strongly depends on the level of p35 which therefore needs to be
precisely regulated. Cdk5r1 KOmice show inverted stratification of
cerebral cortex layers due to an abnormal neuronal migration,
probably impairing the development of a normal cognitive system.
CDK5R1 haploinsufficiency has been invoked as one of the possible
pathogenetic causes of mental retardation in NF1 microdeletion
patients [16] and some variants of this gene have been associated
with isolated mental retardation [54].
The importance of maintaining suitable p35 levels probably
involves different molecular mechanisms aimed at the fine tuning
of its expression through protein stabilization and by regulation
of mRNA stability or translational efficiency by means of the
action of post-transcriptional regulatory factors such as miRNAs.
Dysregulation of miRNAs has also been reported in neurological
and neurodegenerative disorders, which leaves open the question
of whether miRNA dysfunction could be both a cause and/or a
consequence of disease [55].
One of the main CDK5 functions is phosphorylation of proteins
which stabilize microtubules, such as Tau [56]. Abnormal
hyperphosphorylation of Tau, also depending on CDK5 hyper-
activation, appears to be the most deleterious step in neurofibril-
lary degeneration, leading to the formation of neurofibrillary
tangles which are associated with Alzheimer’s disease [57].
Interestingly, miR-107 has been shown to be significantly down-
regulated in Alzheimer’s disease and one of its targets, BACE1, was
found to be increased [47]. Accordingly, an increased level of p35
might be caused by an increase of protein stabilization by BDNF
and/or by an up-regulation following a down-regulation of miR-
107, leading to hyperactivation of CDK5 in Alzheimer’s disease.
Intriguingly, the implication of miR-107 in the regulation of p35
expression indicates that BDNF and BACE1 may be co-regulated
with CDK5R1 in the CNS.
The direct interaction of miR-103 and miR-107 with the
CDK5R1 39-UTR has been proved by functional studies using
luciferase constructs with the whole CDK5R1 39-UTR, or with a
portion of the 39-UTR including one, or in a few cases two,
binding sites. The increased luciferase activity in constructs deleted
of S1 and S8 binding sites suggests their destabilizing function.
Unexpectedly we observed that the deletion of S5/6 and S10 sites
decreased the luciferase activity of R3 and R6 constructs,
respectively. Even if we verified that the mutagenesis did not
create miRNA target sites or recognizable cis-regulatory elements
by using different bioinformatics tools, we can not exclude that
unknown cis-regulatory elements or miRNA target sites or
secondary structures destabilizing mRNA may have been created
by our manipulation. The co-transfection of constructs containing
S1 or S8 sites with miR-103 or miR-107 allowed us to validate the
direct action of the two miRNAs for the S1 target site. This result
can be explained by the lower hybridization free energy with miR-
103 and miR-107 of S1, which has the lowest hybridization free
energy of all the predicted miRNA target sites, based on both
PicTar and RNAhybrid tools. We have to take into account that
the luciferase activity of all the wild-type constructs was reduced
with respect to the control pGL4.71P plasmid, due to the presence
of several post-transcriptional regulatory elements with a inhibi-
tory effect on gene expression all along CDK5R1 39-UTR [23].
This feature made the detection of further decrease of luciferase
activity more difficult. In addition, it is worth noting that S1 is
specific for miR-103 and miR-107, while S8 can also be targeted
by miR-15a and miR-195, whose action may explain the increase
of luciferase activity in the construct deleted of S8 binding site.
The conservation of the CDK5R1 39-UTR sequence during
evolution, the identification of different regulatory regions [23]
and the prediction of several miRNA binding sites with a low
binding free energy pinpoint the functional complexity of this
region in post-transcriptional regulation. We have here demon-
strated that CDK5R1/p35 expression can be modulated by miR-
103 and miR-107, which we found to regulate cellular migration,
accordingly with the roles ascribed to their targets BDNF and p35
in previous studies [11,51]. Knowing that the level of CDK5
activity depends on the amount of p35, we speculate that p35 level
can be finely controlled by both a protein stabilization mechanism
involving BDNF, and by a post-transcriptional expression
modulation involving miR-103 and miR-107, which in turn co-
regulate the level of p35 and its stabilizing factor BDNF.
Studies providing new insights on the identification of miRNAs
targets, may lead to the elucidation of specific molecular pathways,
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also defining their implication in specific cellular functions. The
identification of regulatory sites in CDK5R1 mRNA and their
binding factors, besides contributing to the understanding of the
role of the post-transcriptional regulation of this gene, may address
studies aimed at identifying new pathogenetic mechanisms in
neuronal diseases.
Materials and Methods
miRNA target sites prediction
The prediction of miRNA target sites was performed using the
algorithm PicTar (http://pictar.mdc-berlin.de/). The analysis of
the hybridization free energy between the miRNAs and the
predicted target sites was performed using RNAhybrid (http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid/).
Cell cultures
Human neuroblastoma SK-N-BE (2) cells (ATTC code CRL-
2271) were cultured in RPMI-1640 medium with 10% fetal bovine
serum (FBS), 100 U/ml penicillin-streptomycin, 0.01 mM L-
glutamine, sodium pyruvate 11 g/l and glucose 4.5 g/l. Human
neuroblastoma SH-SY5Y cells (ATTC code CRL-2266) and
human embryonic kidney HEK-293 cells (ATTC code CRL-1573)
were maintained in DMEM medium with 10% FBS, 100 U/ml
penicillin-streptomycin and 0.01 mM L-glutamine. Human pros-
tate carcinoma DU-145 cells (ATTC code HTB-81) were cultured
in RPMI-1640 medium with 10% FCS, 100 U/ml penicillin-
streptomycin, 0.01 mM L-glutamine and 10 mM HEPES.
Human breast tumor MCF-7 cells (ATTC code HTB-22) were
cultured in RPMI-1640 medium with 10% FCS, 100 U/ml
penicillin streptomycin and 0.01 mM L-glutamine (all media
ingredients were obtained from Euroclone, Italy). Cultures were
maintained at 37uC in a 5% CO2 incubator.
Western blotting
The assay was performed under standard conditions. In brief,
equal amounts of proteins were analyzed by 12% SDS-PAGE,
blotted onto nitrocellulose membrane Hybond-enhanced chemi-
luminescence (ECL; Amersham Biosciences UK, Ltd., Buckin-
ghamshire, UK) in a Bio-Rad (CA, USA) Trans-blot apparatus at
100 V for 90 min. Blots were processed by an ECL Plus detection
kit as instructed by the supplier (Amersham Biosciences). The blots
were probed with rabbit anti-p35 (C-19) polyclonal antibody
(Santa Cruz Biotechnology, Inc., CA, USA) and rabbit anti-b-
actin (Sigma-Aldrich, CO, USA) or anti GAPDH antibodies
followed by an alkaline phosphatase-conjugated anti-rabbit IgG
secondary antibody. All experiments were performed three times.
Pre-miRs, anti-miRs and siRNA transfection
dsRNAs that mimic endogenous mature miRNAs (hsa-miR-
103: 59- AGCAGCAUUGUACAGGGCUAUGA-39 and hsa-
miR-107: 59- AGCAGCAUUGUACAGGGCUAUCA-39), the
Pre-miRTM miRNA Precursor Molecules—Negative Control #1
and single-strand anti-miR-103/107 miR inhibitor (oligoribonu-
cleotides), designed to inhibit endogenous hsa-miR-103/107, were
purchased from Ambion (Austin, TX, USA). siRNA ON
TARGET PLUS smart pool CDK5R1 or non-targeting pool
were purchased from Dharmacon (Lafayette, CO, USA). The
transfection experiments were conducted as described by Salvi
[58]. Briefly, SK-N-BE cells were seeded in complete medium at
80% confluence in a 24-well Costar (56104 cells per well). The
cells were transfected into serum-free RPMI, 24 h after seeding, at
50 and 100 nM of double-stranded hsa-miR-103/107 or single-
stranded anti-miR-103/107 miRNA inhibitor or with 50 nM and
100 nM CDK5R1 siRNA, using Lipofectamine 2000 (Invitrogen,
Burlington, ON) transfection reagent according to the manufac-
turer’s instruction. The transfection had a very high efficiency as
proved by measuring of mature miRNA molecules levels by qRT-
PCR after transfection (data not shown). The transfection medium
was replaced, after 24 h, with RPMI supplemented with 10% fetal
bovine serum. The conditioned media and cell extracts were
prepared for analysis 48 and 72 h after the transfection.
Polysomal RNA extraction
SK-N-BE cells (46106), transfected as described above, were
incubated for 3 minutes with 0.01 mg/ml cycloheximide at 37uC
then the plate was put on ice. The media was removed and the
cells were washed twice with cold phosphate buffer saline (PBS) +
cycloheximide 0.01 mg/ml. Cells were directly lysed on the plate
with 300 ml cold lysis buffer [10 mM NaCl, 10 mM MgCl2,
10 mM Tris–HCl, pH 7.5, 1% Triton X-100, 1% sodium
deoxycholate, 0.2 U/ml RNase inhibitor (Fermentas, Burlington,
CA), 1 mM dithiothreitol and 0.01 mg/ml cycloheximide],
scraped and transferred to an Eppendorf tube. The extracts were
centrifuged for 5 min at 12000 g at 4uC. The supernatant was
frozen in liquid nitrogen and stored at 280uC or loaded directly
onto a 15–50% linear sucrose gradient containing 30 mM Tris–
HCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged in
an SW41 rotor for 100 min at 180000 g. Fractions (polysomal and
sub-polysomal) were collected monitoring the absorbance at
254 nm and treated directly with 0.1 mg/ml proteinase K for
2 hours at 37uC. After phenol–chloroform extraction and
isopropanol precipitation, polysomal and sub-polysomal RNAs
were resuspended in 30 ml of RNAse free water and then
repurified with RNeasy kit (Qiagen, Hilden, Germany).
Real-time PCR
The total RNAs from transfected and nontransfected cells were
isolated using TRIzol reagent (Invitrogen), according to the
manufacturer’s instructions. Purity of RNAs (A260/A280 value of
1.8–2.1) and concentration was measured using Nanodrop
spectrophotometer.
For a quantitative analysis of mature miRs, a two-step Taq-Man
real-time PCR analysis was performed, using primers and probes
obtained from Applied Biosystems (Foster, CA, USA). cDNA was
synthesized from total RNA (50 ng) in 15 ml reactions, using
reverse transcriptase and the stem–loop primer for miR-15a
(ID000389), miR-16 (ID000391), miR-103 (ID000439), miR-107
(ID000443), miR-195 (ID000494), miR-34a (ID000426)\ or
RNU6B (endogenous control as recommended by Applied
Biosystems; ID001093) contained in the TaqMan MicroRNA
Reverse Transcription kit (Applied Biosystems). The reverse
transcriptase reaction was performed by incubating the samples
at 16uC for 30 min, 42uC for 30 min, and 85uC for 5 min. The
PCR reaction (20 ml) contained 1.3 ml of reverse transcriptase
product, 10 ml of Taq-Man 26Universal PCR Master Mix, and
1 ml of the appropriate TaqMan MicroRNA Assay (206)
containing primers and probes for the miR of interest. The PCR
mixtures were incubated at 95uC for 10 min, and this was followed
by 40 cycles of 95uC for 15 s and 60uC for 60 s. The expression of
miRs was based on the DCT method, using RNU6B as an
endogenous control.
For the measurement of the CDK5R1 transcript from total RNA
or from polysomal/subpolysomal fractions, total cDNA was
synthesized using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). Real-Time PCR was performed using
Kapa SYBR fast qPCR master mix (Kapa Biosystems, Woburn,
MA, USA) and primers CDK5R1 fw: TGAGCGGGTCTAGTG-
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GAAAG, CDK5R1 rev: AGCAGCAGACAAGGGGGTAG,
GAPDH fw: TGCACCACCAACTGCTTAGC, GAPDH rev:
GGCATGGACTGTGGTCATGAG, Alu fw: GAGGCTGAGG-
CAGGAGAATCG and Alu rev: GTCGCCCAGGCTGGAGTG.
The PCR reaction (10 ml) contained 1 ml of reverse transcriptase
product, 5 ml of TaqMan 26 Universal PCR Master Mix, and
0.2 ml of each primer. The PCR mixtures were incubated at 95uC
for 3 min, and this was followed by 40 cycles of 95uC for 10 s,
60uC for 20 s and 72uC for 10 s. The expression of CDK5R1 was
based on the DDCT method, using GAPDH or Alu as internal
controls. All PCRs were performed in triplicate using an iQ5 Real
Time PCR detection system (Bio-Rad).
In vitro scratch assay
320,000 SK-N-BE cells were seeded in 30-mm diameter Petri-
dishes in complete medium, they were grown to 80% confluency
and then transfected with 50 nM and 100 nM pre-miR-107, pre-
miR-103, CDK5R1 siRNA and with 50/100 nM negative control
siRNA and miR as previously described. After 24 h the
transfection medium was replaced with fresh medium. When the
cells reached the 100% confluence a scratch was made through the
cell layer using a sterile micropipette tip. After washes with PBS,
serum-free medium was added. The images of the wounded area
were captured immediately after the scratch (T0) and 8 and 24 h
later (T8 and T24) to monitor the cell migration into the wounded
area. The migration abilities were quantified by measuring the
area of the scratched regions using the ImagePro Plus 4.5 software.
The experiment was performed twice.
39-UTR constructs
The entire human CDK5R1 39-UTR, or segments of it, were
PCR-amplified from PAC144O22 using PFU Taq polymerase
(Promega, San Diego, CA, USA) with proofreading activity and
using primers containing flanking XbaI recognition sequence
(Table 2).
The PCR products were ligated in the XbaI restriction site
downstream of the Renilla luciferase coding region of the pGL4.71
vector (Promega), in which the SV40 promoter region from the
pGL3-Promoter vector (Promega) was previously cloned to obtain
the pGL4.71P plasmid. The correct orientation of the insert was
verified by direct sequencing using the Big DyeTM Terminator
Cycle Sequence Ready Reaction Kit and a 3130XL ABI Prism
Genetic Analyzer (Applied Biosystem).
The constructs deleted of the miR target sites were generated
using the wt plasmids as templates and using two complementary
specific 30 nt primers carrying the desired mutation (Table 3). We
verified that the deletion of the miRNA sites did not create novel
binding sites for the selected miRNAs and that no known
regulatory elements were created using UTRscan at http://
itbtools.ba.itb.cnr.it/utrscan and RegRNA at http://regrna.mbc.
nctu.edu.tw/. A mixture with 106buffer and 1.25 U of Pfu Turbo
DNA Polymerase (Stratagene, CA, USA), 62.5 ng of each primer,
0.4 mM dNTPs and 5–50 ng template plasmid was incubated at
95uC for 30 s followed by 18 cycles at 95uC for 30 s, 55uC for
1 min and 68uC for 2 min per Kb plasmid length. Then the 5 U
DpnI enzyme (Fermentas, St. Leon-Rot, Germany) for 5 h at
37uC were used to degrade the template plasmid, which is
methylated because of bacterial origin.
Luciferase assay
For luciferase activity assays, 1.36105 SK-N-BE cells per well
were seeded in 12-well dishes in 1 ml of medium 24 h before
transfection. Cells were transfected at 60–70% confluence using
2 ml of Lipofectamine 2000 (Invitrogen) with 150 ng of the
pGL4.71P constructs containing different CDK5R1 39-UTR
fragments. Transfection efficiency was .90% as measured by cell
counting after transfection of a GFP expressing plasmid. To
normalize the value of Renilla luciferase activity for transfection
efficiency and cell viability after transfection, the pGL3-Promoter
Firefly luciferase reporter gene was cotransfected (150 ng). 24 h
Table 2. Oligonucleotides used to generate the 39-UTR luciferase constructs of the human CDK5R1 gene.
Fragment Size (bp) Sequence
PCR annealing
temperature (6C)
UTR 2688 Fw: 59 GCTCTAGAATCGGTGAGCACTGTGCCTG 39 62
Rev: 59 GCTCTAGAGAATCAGCACAGTACAAAAATAAAT 39
Fr1 662 Fw: 59 GCTCTAGAATCGGTGAGCACTGTGCCTG 39 62
Rev: 59 GCTCTAGAAGCAGCAGACAAGGGGGTAG 39
Fr2 357 Fw: 59 GCTCTAGATGAGCGGGTCTAGTGGAAAG 39 58
Rev: 59 GCTCTAGAGTATGGCATCCCTCACCTTG 39
Fr3 365 Fw: 59 GCTCTAGACAAGGTGAGGGATGCCATAC 39 56
Rev: 59 GCTCTAGAGAAAGAAAATCAATAAAGTACAC 39
Fr4 320 Fw: 59 GCTCTAGATGCTGGAATAGGGACCTGG 39 56
Rev: 59 GCTCTAGAGTGCTGTGTGAAGTCTGTG 39
Fr5 346 Fw: 59 GCTCTAGAGGGACTGTCAGATAATCGGTG 39 60
Rev: 59 GCTCTAGATCCAGGTTTACAAGAAAAAGAGAA 39
Fr6 159 Fw: 59 GCTCTAGAGGCTTCACACTGAGGGAACTA 39 58
Rev: 59 GCTCTAGAGTAGGTTTTTTTTTATTGTTGATC 39
Fr7 213 Fw: 59 GCTCTAGATTTAGATCAACAATAAAAAAAAAC 39 54
Rev: 59 GCTCTAGATCCAGGTTTACAAGAAAAAGAGAA 39
XbaI recognition site sequence is bolded.
doi:10.1371/journal.pone.0020038.t002
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after transfection cells were washed with PBS and lysed with
passive lysis buffer (Promega), the Renilla and Firefly luciferase
activity were measured using the Dual-Glo Luciferase Assay
System (Promega) in a single channel luminometer.
For transient transfection of SK-N-BE cells with pre-miRs and
luciferase constructs, 3.56105 cells were seeded in 6-well plates
and then transfected with 100 nm double-stranded hsa-miRs, 24 h
after seeding, and with the luciferase reporter constructs (300 ng),
48 h after seeding, using Lipofectamine 2000 transfection reagent
according to the manufacturer’s instruction. 72 h after seeding, the
luciferase activity was determined as described above. Each
experiment was performed at least three times.
Statistical analysis
Histograms represent the mean values, and bars indicate
standard deviation of the mean. The statistical significance of
the results was determined using Student’s t-test, with data
considered significant when p,0.05. The degree of linear
relationship between miRNAs and p35 expression was calculated
using Pearson’s correlation coefficient using the mean values of
three experiments.
Supporting Information
Figure S1 Conservation of miR-103 target sites and
hybridization analysis with CDK5R1 39-UTR. Conserva-
tion of the predicted miR-103 target sites in the 39-UTR of human
CDK5R1 (RefSeq Accession Number NM_003885) comparing five
different species (hs, Homo sapiens; pt, Pan troglodytes; mm, Mus
musculus; rt; Rattus norvegicus; cf, Canis familiaris) and prediction of the
mininum free energy hybridization (mfe) of microRNA/target
duplexes assessed by the RNAhybrid program.
(DOC)
Figure S2 Conservation of miR-107 target sites and
hybridization analysis with CDK5R1 39-UTR. Conserva-
tion of the predicted miR-107 target sites in the 39-UTR of human
CDK5R1 (RefSeq Accession Number NM_003885) comparing five
different species (hs, Homo sapiens; pt, Pan troglodytes; mm, Mus
musculus; rt; Rattus norvegicus; cf, Canis familiaris) and prediction of the
mininum free energy hybridization (mfe) of microRNA/target
duplexes assessed by the RNAhybrid program.
(DOC)
Figure S3 Silencing of p35 by CDK5R1 siRNA. p35
amounts detected by western blot in CDK5R1 siRNA, negative
control (C2 siRNA) and untransfected SK-N-BE cells. A) The p35
protein levels are decreased by 41% (**p,0.01) and 38%
(*p,0.05) in SK-N-BE transfected with 50 nM and 100 nM
siRNA p35, respectively, 48 h after transfection, compared to
untransfected cells. B) The p35 protein levels are decreased by
42% and 35% (**p,0.01) in SK-N-BE transfected with 50 nM
and 100 nM CDK5R1 siRNA, respectively, 72 h after transfection,
compared to untransfected cells.
(TIF)
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